NICE recommends new targeted treatment for early breast cancer


16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit around 4,000 patients in England.

Final draft guidance1 published on 17 June gives provisional approval of abemaciclib in combination with hormone therapy as an option after surgery. It is recommended for people with hormone receptor positive, HER2 negative, node positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour.

Read BMJ article

Michael Wonder

Posted by:

Michael Wonder